You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Drug for Hepatitis C Infection

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000444528.06303.4c
Drug Watch
Abstract

* Simeprevir (Olysio) is a new protease inhibitor approved for the treatment of adults with hepatitis C viral infection. Simeprevir should be used as part of a combination therapy treatment plan.

* Genotype 1a hepatitis C virus with the NS3 Q80K polymorphism will not respond well to simeprevir therapy.

* Common adverse effects are rash (including photosensitivity), pruritis, and nausea.

Author Information

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2014 Lippincott Williams & Wilkins. All rights reserved.